.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Spotlight

CME Opportunities

SpecialtySee All >

Breast Cancer
Lung Cancer
Gastrointestinal Cancer
Genitourinary Cancers
Ovarian Cancer
Prostate Cancer
Melanoma & Skin Cancer
MCL
MPN
CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Gynecologic Oncology
Hematologic Oncology
Immuno-Oncology
Multiple Myeloma
Urothelial Cancer

Advertise
About OncLive
Editorial Board
MJH Life Sciences brands
Contact Us
Privacy
Terms & Conditions
Do Not Sell My Information

2 Clarke Drive
Suite 100
Cranbury, NJ 08512

Post-Conference Perspectives: Peripheral T-Cell Lymphoma

EP. 1: Peripheral T-Cell Lymphoma Classifications and CD30 Testing

January 28th 2019

EP. 2: T-Cell Lymphoma Differential Diagnosis and CD30 Treatment

January 28th 2019

EP. 3: Brentuximab Vedotin Overview and Treatment Advice

January 28th 2019

EP. 4: The ECHELON-2 Trial Presented at ASH 2018

January 28th 2019

EP. 5: PTCL Community Treatment and Future Advancements

January 28th 2019

EP. 6: An Overview of Peripheral T-Cell Lymphoma

January 28th 2019

EP. 7: Treating Patients With CD30-Positive PTCL

January 28th 2019

EP. 8: The Impact of Brentuximab Vedotin as PTCL Treatment

January 28th 2019

EP. 9: PTCL Treatment in the Community Setting

January 28th 2019

EP. 10: The Current Unmet Needs in PTCL Treatment and Prospects

January 28th 2019